Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21)

The summary for the Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21): -Purpose. With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) encourage grant applications that: (a) address the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC); (b) propose development of animal models for HCC; (c) propose novel approaches to prevent HCC malignancy; (d) propose therapeutic or diagnostic tools for reliable prognostic indicators for HCC; and/or (e) develop therapeutic approaches to minimize morbidity and mortality associated with HCC in humans. The primary focus of the proposed project must be on the basic biology, prevention, and/or treatment of liver cancer. Applications solely concerned with population studies and epidemiology will not be supported in connection with this FOA. -Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with two FOAs of similar scientific scope: (1) PA-08-243, for research projects using the R01 mechanism; and (2) PAR-08-245, for program project grants under the P01 mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known

Federal Grant Title:	Etiology, Prevention, and Treatment of Hepatocellular Carcinoma(R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-08-244
Type of Funding:	Grant
CFDA Numbers:	93.273
CFDA Descriptions:	Alcohol Research Programs
Current Application Deadline:	Sep 07, 2011
Original Application Deadline:	Sep 07, 2011
Posted Date:	Aug 19, 2008
Creation Date:	Dec 05, 2008
Archive Date:	Oct 08, 2011
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession; Units of Local Governments.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Limited Competition: Alcohol-associated Hepatitis Clinical Network Integrated Treatment C...; • Limited Competition: Alcohol-associated Hepatitis Clinical Network Integrated Treatment C...; • Model Continuums of Care Initiative (MCCI) to Advance Health Equity and End Health Dispari...; • Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinica...; • Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clin...; • Mechanisms of Alcoholic Pancreatitis; • Alcohol Abuse and Hiv/Aids in Resource-Poor Societies; • Mechanisms of Alcohol-Induced Tissue Injury
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...